(Q44529239)

English

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

scientific article published in August 2003

In more languages
default for all languages
No label defined

No description defined

Statements

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm (English)
Robert J Friedlander
Rochelle Strenger

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit